CytoMed Therapeutics (GDTC) highlights γδ T cell AML research in 6-K

Rhea-AI Filing Summary

CytoMed Therapeutics Limited filed a Form 6-K to share that it issued a press release about new collaborative research with The University of Texas MD Anderson Cancer Center. The publication describes research demonstrating the potential of CytoMed’s allogeneic γδ T cells to treat acute myeloid leukemia, a type of blood cancer. The filing itself mainly serves to make this scientific update available to investors and includes the full press release as an exhibit.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-41677

CytoMed Therapeutics Limited

(Exact name of registrant as specified in its charter)

1 Commonwealth Lane

#08-22

Singapore 149544

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On October 2, 2025, CytoMed Therapeutics Limited (the “Company”) issued a press release announcing a publication based on collaborative research with The University of Texas, MD Anderson Cancer Center, which demonstrates the potential of the Company’s Allogeneic γδ T Cells to treat Acute Myeloid Leukemia.

A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Press Release dated October 2, 2025, titled: CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited
	By:	/s/ CHOO Chee Kong
	Name:	CHOO Chee Kong
Date: October 2, 2025	Title:	Director and Chairman

FAQ

What did CytoMed Therapeutics (GDTC) report in this Form 6-K?

CytoMed Therapeutics reported that it issued a press release about a new scientific publication from collaborative research with The University of Texas MD Anderson Cancer Center on the potential of its allogeneic γδ T cells to treat acute myeloid leukemia.

What is the focus of CytoMed Therapeutics' collaborative research mentioned in the filing?

The collaborative research focuses on demonstrating the potential of CytoMed Therapeutics’ allogeneic γδ T cells as a treatment for acute myeloid leukemia.

Which institution is collaborating with CytoMed Therapeutics (GDTC) in this research?

CytoMed Therapeutics is collaborating with The University of Texas, MD Anderson Cancer Center on this research.

What exhibit is included with CytoMed Therapeutics' October 2025 Form 6-K?

The filing includes Exhibit 99.1, a press release dated October 2, 2025 titled “CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia.”

Does the CytoMed Therapeutics (GDTC) Form 6-K contain financial results or transaction details?

The Form 6-K describes a scientific publication and furnishes a related press release. It does not present financial results or major transaction information in the provided content.

Who signed the CytoMed Therapeutics Form 6-K filed in October 2025?

The Form 6-K was signed on behalf of CytoMed Therapeutics Limited by CHOO Chee Kong, who is identified as Director and Chairman.